View Older Stories View More Recent Stories

Jan 24, 2022 05:00PM Deciphera Pharmaceuticals (DCPH) Reports Results from the INTRIGUE Phase 3 Clinical Study
Jan 24, 2022 05:00PM Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
Jan 10, 2022 07:00AM Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
Jan 3, 2022 07:00AM Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 21, 2021 08:44AM Deciphera Pharmaceuticals (DCPH) Announces Approval of QINLOCK in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Dec 21, 2021 08:44AM Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Nov 30, 2021 08:30AM Deciphera Pharmaceuticals (DCPH) will implement an organizational restructuring that will result in a workforce reduction of approximately 35%
Nov 30, 2021 08:30AM Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
Nov 22, 2021 07:02AM Deciphera Pharmaceuticals (DCPH) Receives European Commission Approval of QINLOCK for tTreatment of Fourth-Line Gastrointestinal Stromal Tumor
Nov 22, 2021 07:00AM Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Nov 5, 2021 07:01AM Deciphera Pharmaceuticals (DCPH) INTRIGUE Phase 3 Clinical Study Did Not Meet the Primary Endpoint in GIST
Nov 5, 2021 07:00AM Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study
Nov 2, 2021 04:01PM Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results
Oct 26, 2021 07:00AM Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021
Oct 12, 2021 07:00AM Deciphera Pharmaceuticals (DCPH) Announces QINLOCK Approved in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Oct 12, 2021 07:00AM Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Oct 7, 2021 09:00AM Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 17, 2021 07:04AM Deciphera Pharmaceuticals (DCPH) Presents New Clinical Study Results Across Pipeline at ESMO
Sep 17, 2021 07:00AM Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021
Sep 10, 2021 07:00AM Deciphera Pharmaceuticals to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Congress 2021
Sep 2, 2021 07:00AM Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
Aug 3, 2021 04:01PM Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results
Jul 27, 2021 07:00AM Deciphera Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 3, 2021
Jun 30, 2021 04:01PM Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene
Jun 4, 2021 09:00AM Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 27, 2021 07:00AM Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
May 4, 2021 04:22PM Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results
Apr 28, 2021 07:00AM Deciphera Pharmaceuticals, Inc. to Present at the Truist Securities Life Sciences Summit
Apr 27, 2021 07:00AM Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021
Mar 31, 2021 04:57AM China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
Mar 31, 2021 04:57AM China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
Mar 2, 2021 07:00AM Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
Feb 18, 2021 07:00AM Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference
Feb 9, 2021 04:01PM Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results
Feb 4, 2021 07:00AM Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day
Feb 2, 2021 07:00AM Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021
Jan 11, 2021 07:05AM Deciphera Pharmaceuticals (DCPH) Provides Corporate Update and Highlights Key 2021 Corporate Milestones
Jan 11, 2021 07:00AM Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones
Jan 5, 2021 07:23AM Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
Nov 30, 2020 07:00AM Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor
Nov 24, 2020 04:01PM Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 23, 2020 07:00AM The Boston Globe Names Deciphera a Top Place to Work for 2020
Nov 11, 2020 07:01AM Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
Nov 11, 2020 07:00AM Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual M
Nov 10, 2020 07:00AM Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
Nov 6, 2020 08:00AM Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK® (Ripretinib) in a Multi-Regional Agreement
Nov 5, 2020 04:30PM New Drug for Gastrointestinal Stromal Tumours (GIST) to be Launched in Australia, New Zealand and South East Asia Following Distribution Agreement
Nov 5, 2020 04:01PM Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results
Oct 28, 2020 07:00AM Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020
Sep 18, 2020 07:04AM Deciphera Pharmaceuticals (DCPH) Presents Data from QINLOCK Program in Patients with Gastrointestinal Stromal Tumor at ESMO
View More Recent Stories View Older Stories